Comments
All work, little pay for Icahn in Amylin
02.07.2012. | NEW YORK (Reuters) - It took Carl Icahn four years, a bitter proxy fight and litigation to make an estimated 22 percent return on Amylin Pharmaceuticals Inc. He could have made about the same amount of money had he just bought a basket of healthcare stocks instead....
